O USO DE ÍNDICES DE AVALIAÇÃO COMO ARGUMENTO DE QUALIDADE DAS INSTITUIÇÕES DE EDUCAÇÃO SUPERIOR

CpGs differentially methylated in lung DNA in relation to COPD vs. non-smokers (P < 0.01). (CSV 273 kb

Additional file 4: Table S3. of DNA methylation profiling in peripheral lung tissues of smokers and patients with COPD

CpGs differentially methylated in lung DNA in relation to COPD vs. smokers (P < 0.001). (CSV 1 kb

Additional file 12: Table S11. of DNA methylation profiling in peripheral lung tissues of smokers and patients with COPD

Top 100 CpGs differentially methylated along with five CpG sites chosen for validation in lung DNA in relation to COPD vs. non-smokers shown in heatmap (Fig. 3b). (CSV 2 kb

Additional file 1: Figures S1-S13. of DNA methylation profiling in peripheral lung tissues of smokers and patients with COPD

Figure S1.Boxplot shows distribution of pre-processed DNA methylation level (β values) from all the samples and different groups used for comparison. Figure S2.Venn diagrams shows DNA methylation loci that were identified to be overlapping and or shared between Non-smokers vs. Smokers compared to Non-smokers vs. COPD and Smoker vs. COPD. Figure S3-S9. Target sequence for the NOS1AP (cg26663636), TNFAIP2 (cg18620571), BID (cg01388022), GABRB1 (cg15393297), ATXN7/THOC7 (cg07753241), AHRR (cg21161138) and SERPINA1 (cg02181506) amplicons. Figure S10-13. Pyrosequencing validation of additional CpG sites for NOS1AP, TNFAIP2, BID, and ATXN7/THOC7. (PPTX 1.93 mb